Challenges and considerations for development of therapeutic proteins in pediatric patients

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S103-S115

  Zhang, Yi ^a,b   Wei, Xiaohui ^a   Bajaj, Gaurav ^c   Barrett, Jeffrey S ^d   Meibohm, Bernd ^e   Joshi, Amita ^a   Gupta, Manish ^a,c  

^a GENENTECH INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

dosing; pediatrics; pharmacometrics; PK PD; therapeutic proteins

Indexed keywords

PROTEIN; THERAPEUTIC PROTEIN; UNCLASSIFIED DRUG; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ARTICLE; BODY WEIGHT; CHILD; CHILD HEALTH CARE; CLINICAL PHARMACOLOGY; CLINICAL STUDY; DECISION TREE; DISEASE COURSE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFORMATION; DRUG SAFETY; HUMAN; ONTOGENY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CHILD; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 84923378180     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.382     Document Type: Article

References (59)

1. Dimitrov DS,. Therapeutic proteins. Methods Mol Biol. 2012; 899: 1-26.
2. Olski TM, Lampus SF, Gherarducci G, Saint Raymond A,. Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol. 2011; 67: 245-252.
3. FDA, Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling. 2014. Draft guidance Accessed April 12 2013; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM341394.pdf.
4. EMA, Official Journal of the European Union. Communication from the Commission: Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies /C 234/01) 2010 August 31 2008; http://ec.europa.eu/health/files/eudralex/vol-1/com-2008-jo243/com-2008-243-en.pdf/.
5. Morford LL, Bowman CJ, Blanset DL, et al. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. Birth Defects Res B Dev Reprod Toxicol. 2011; 92 (4): 359-380.
6. FDA,. Guidance for Industry Nonclinical Safety Evaluation of Pediatric Drug Products. 2013. Accessed June 2006; 15: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf.
7. European Medicines Agency (EMA),. Committee for Human Medicinal Products (CHMP), Guideline on the need for nonclinical testing in juvenile animals on human pharmaceuticals for paediatric indications. 2008. Accessed June 15 2013; http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003305.pdf.
8. Xu Z, Davis HM, Zhou H,. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013; 137 (2): 225-247.
9. Anderson BJ, Holford NH,. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child. 2013; 98 (9): 737-744.
10. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 18 (12): 1157-1167.
11. Yanni S,. Disposition and interaction of biotherapeutics in pediatric populations. Curr Drug Metab. 2012; 1 (7): 882-900.
12. Agoram BM, Martin SW, van der Graaf PH,. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007; 12 (23-24): 1018-1024.
13. Wang DD, Zhang S, Zhao H, Men AY, Parivar K,. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009; 49 (9): 1012-1024.
14. Tabrizi MA, Tseng CM, Roskos LK,. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11 (1-2): 81-88.
15. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD,. Have we overestimated the benefit of human(ized) antibodies? MAbs. 2010; 2 (6): 682-694.
16. Chirmule N, Jawa V, Meibohm B,. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012; 14 (2): 296-302.
17. FDA, Guidance for the industry: Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. 2003. Accessed April 10 2013; http://www.fda.gov/cber/guidelines.htm.
18. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002; 15 (7): 966-971.
19. Pescovitz MD, Knechtle S, Alexander SR, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008; 12 (4): 447-455.
20. FDA, Clinical pharmacology review for Tocilizumab pediatric indication. 2013. Accessed April 10 2013; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM343574.pdf.
21. Levy G., Pharmacologic target-mediated drug disposition Clin Pharmacol Ther 1994; 56 (3): 248-252.
22. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28 (6): 507-532.
23. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN,. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46 (7): 1851-1856.
24. Kawamoto N, Kaneko H, Takemura M, et al. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children Pediatr Allergy Immunol 2006; 17 (2): 125-133.
25. Zisowsky J, Krause A, Dingemanse J,. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010; 2: 364-388.
26. Xolair®,. (Omalizumab) [package, Insert] South, Francisco. CA: Genentech Inc. 2010.
27. Abernethy DR, Burckart GJ,. Pediatric dose selection. Clin Pharmacol Ther. 2010; 87 (3): 270-271.
28. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009; 24 (1): 25-36.
29. Holford NH,. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996; 30 (5): 329-332.
30. Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012; 1 (2): 119-135.
31. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H,. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005; 45 (3): 246-256.
32. Humira®,. (Adalimumab) [package, insert]. North, Chicago. IL: Abbott Laboratories. 2002.
33. FDA, Adalimumab Clinical pharmacology review. 2007; http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092772.pdf.
34. Ilaris®,. (Canakinumab) [package, insert]. East, Hanover. NJ: Novartis Pharmaceuticals Corporation. 2011.
35. FDA, Canakinumab clinical pharmacology review. 2009. Accessed April 10, 2013; http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/125319s000-SumR.pdf.
36. Orencia®,. (Abatacept) [package, insert]. Princeton. NJ Bristol-Myers Squibb. 2011.
37. FDA, Minutes for the November 5, Meeting of the Pediatric Oncologic Drugs Advisory Committee. 2014. Accessed August 2 2013; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM378968.pdf.
38. Barrett JS, Della Casa, Alberighi O, Laer S, Meibohm B,. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012; 92 (1): 40-49.
39. Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012; 91 (5): 926-931.
40. Chen Y, Balthasar JP,. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J. 2012; 14 (4): 850-859.
41. Ferl GZ, Wu AM, DiStefano JJ, 3rd., A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn) Ann Biomed Eng 2005; 33 (11): 1640-1652.
42. Garg A, Balthasar JP,. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007; 34 (5): 687-709.
43. Urva SR, Yang VC, Balthasar JP,. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010; 99 (3): 1582-1600.
44. Shah DK, Betts AM,. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012; 39 (1): 67-86.
45. Wang Y, Jadhav PR, Lala M, Gobburu JV,. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012; 52 (10): 1601-1606.
46. Retout S, Duffull S, Mentre F, Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65 (2): 141-151.
47. Meibohm B, Laer S, Panetta JC, Barrett JS,. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005; 7 (2): E475-E487.
48. FDA, FDA website for approved drugs. 2014 Accessed April 12 2014; http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
49. Actemra®,. (Tocilizumab) [packet insert]. South San Francisco, CA: Genentech Inc. 2011.
50. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008; 26 (3): 399-405.
51. Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium J Clin Oncol. 2009; 27 (30): 5102-5108.
52. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012; 143 (2): 365-374.
53. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet. 2012; 1 (6): e1-18.
54. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33 (7): 946-964.
55. Kovarik JM, Gridelli BG, Martin S, et al. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant. 2002; 6 (3): 224-230.
56. Soliris®,. (Eculizumab) [package, insert]. Cheshire. CT: Alexion Pharmaceuticals Inc. 2011.
57. Grundy J, Pan W, Kugathasan S,. Pharmacokinetics and pharmacodynamics of natalizumab in a Phase 2 study of adolescent patients with Crohn's disease. J Pediatr Gastroenterol Nutr. 2005; 41 (4): 538.
58. Arcalyst®,. (Rilonacept). Package insert. Regeneron Pharmaceuticals. Inc. 2014.
59. Portier K, Tolson JK, Roberts SM,. Body weight distributions for risk assessment. Risk Anal. 2007; 27 (1): 11-26.